Alliance Global raised the firm’s price target on Journey Medical (DERM) to $16 from $10 and keeps a Buy rating on the shares post the Q3 report. The firm cites enthusiasm in the Emrosi launch for the target boost. It increased its peak revenue forecast to $250M from $200M for the drug.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM:
- Buy Rating for Journey Medical Corp Driven by Emrosi’s Market Success and Growth Potential
- Journey Medical Corporation Reports Strong Q3 2025 Growth
- Journey Medical reports Q3 EPS (9c), consensus (4c)
- Fourteen new option listings on November 12th
- Journey Medical Corporation (DERM) Q3 Earnings Cheat Sheet